ID: ALA4080381

Max Phase: Preclinical

Molecular Formula: C24H34N4O7S2

Molecular Weight: 554.69

Molecule Type: Small molecule

Representations

Canonical SMILES:  COc1cc(COc2ccc3c(c2)NCCN([C@H](CCCCNS(C)(=O)=O)C(=O)NO)S3)cc(OC)c1

Standard InChI:  InChI=1S/C24H34N4O7S2/c1-33-19-12-17(13-20(14-19)34-2)16-35-18-7-8-23-21(15-18)25-10-11-28(36-23)22(24(29)27-30)6-4-5-9-26-37(3,31)32/h7-8,12-15,22,25-26,30H,4-6,9-11,16H2,1-3H3,(H,27,29)/t22-/m1/s1

Standard InChI Key:  AYXTUWKURHDRRP-JOCHJYFZSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 554.69

Molecular Weight (Monoisotopic): 554.1869

AlogP: 2.61

#Rotatable Bonds: 13

Polar Surface Area: 138.46

Molecular Species: NEUTRAL

HBA: 10

HBD: 4

#RO5 Violations: 1

HBA (Lipinski): 11

HBD (Lipinski): 4

#RO5 Violations (Lipinski): 2

CX Acidic pKa: 8.72

CX Basic pKa: 3.00

CX LogP: 0.91

CX LogD: 0.89

Aromatic Rings: 2

Heavy Atoms: 37

QED Weighted: 0.13

Np Likeness Score: -0.63

References

1. Ouvry G, Berton Y, Bhurruth-Alcor Y, Bonnary L, Bouix-Peter C, Bouquet K, Bourotte M, Chambon S, Comino C, Deprez B, Duvert D, Duvert G, Hacini-Rachinel F, Harris CS, Luzy AP, Mathieu A, Millois C, Pascau J, Pinto A, Polge G, Reitz A, Reversé K, Rosignoli C, Taquet N, Hennequin LF..  (2017)  Identification of novel TACE inhibitors compatible with topical application.,  27  (8): [PMID:28274635] [10.1016/j.bmcl.2017.02.035]

Source

Source(1):

• Scientific Literature